

*Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders.  
In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.*

[Translation]

### **Results of the Exercise of Voting Rights of the 18th Term Annual Shareholders Meeting**

The results of the exercise of voting rights of the 18th Term Annual Shareholders Meeting of Astellas Pharma Inc. (the “Company”) held on June 22, 2023 are as follows.

1. Details of matters to be resolved

First Proposal: Election of Seven (7) Directors (Excluding Directors Who Are Audit & Supervisory Committee Members)  
To elect Dr. Kenji Yasukawa, Mr. Naoki Okamura, Mr. Katsuyoshi Sugita, Mr. Takashi Tanaka, Ms. Eriko Sakurai, Mr. Masahiro Miyazaki and Dr. Yoichi Ohno

Second Proposal: Election of One (1) Director Who Is an Audit & Supervisory Committee Member  
To elect Ms. Rie Akiyama

2. Numbers of voting rights for approval of, against and abstaining from each of the matters to be resolved, requirements for each of the matters to be resolved to be approved and the results for each resolution

Matters to be resolved	Approval	Against	Abstention	Proportion of approval	Result	Approval requirements
First Proposal						
Kenji Yasukawa	14,740,402	302,312	2,774	97.9%	Approval	Note)
Naoki Okamura	14,626,967	415,995	2,525	97.2%	Approval	
Katsuyoshi Sugita	14,609,378	433,440	2,671	97.1%	Approval	
Takashi Tanaka	14,592,572	450,150	2,765	96.9%	Approval	
Eriko Sakurai	14,798,239	244,571	2,681	98.3%	Approval	
Masahiro Miyazaki	14,779,900	262,910	2,681	98.2%	Approval	
Yoichi Ohno	14,780,683	262,127	2,681	98.2%	Approval	
Second Proposal						
Rie Akiyama	14,868,496	177,034	2,681	98.8%	Approval	Note)

Note) Approval requires i) the attendance of shareholders possessing at least one-third (1/3) of the voting rights of shareholders who are eligible to exercise voting rights and ii) an affirmative vote of a majority of the voting rights of shareholders in attendance.